万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>耳鼻喉科学

Clinical and Experimental Otorhinolaryngology《临床与实验耳鼻咽喉》 (官网投稿)

简介
  • 期刊简称CLIN EXP OTORHINOLAR
  • 参考译名《临床与实验耳鼻咽喉》
  • 核心类别 SCIE(2024版), 目次收录(维普), 目次收录(知网),外文期刊,
  • IF影响因子
  • 自引率4.40%
  • 主要研究方向医学-OTORHINOLARYNGOLOGY耳鼻喉科学

主要研究方向:

等待设置主要研究方向
医学-OTORHINOLARYNGOLOGY耳鼻喉科学

Clinical and Experimental Otorhinolaryngology《临床与实验耳鼻咽喉》(季刊). Clinical and Experimental Otorhinolaryngology (Clin Exp Otorhinolaryngol, CEO) is an int...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊网址:https://www.e-ceo.org/

3、投稿网址:http://submit.e-ceo.org/

4、官网邮箱:editor.eceo@gmail.com(编辑部)

kicubi@daum.net(主编)

5、官网电话:+82-2-711-9091(编辑部)

6、期刊刊期:季刊,逢季中月出版。

2022117日星期一

                              

 

投稿须知【官网信息】

 

Instructions for Authors

Clinical and Experimental Otorhinolaryngology (Clin Exp Otorhinolaryngol, CEO) is the official English language journal of the Korean Society of Otorhinolaryngology-Head and Neck Surgery.

Published four times per year on the last day of February, May, August, and November, the journal reports clinical and other investigations relating to otorhinolaryngology and its allied sciences, publishing full-length original papers, reviews, guidelines, correspondences, and editorials. To submit a manuscript to the CEO, it is advised to first carefully read the aims and scope section of this journal, as it provides information on the editorial policy and the category of the papers that it accepts from authors. Manuscripts should be prepared for submission to CEO according to the following instructions. CEO adheres completely to the guidelines and best practices published by professional organizations, including “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” from International Committee of Medical Journal Editors (ICMJE; http://www.icmje.org) and “Principles of Transparency and Best Practice in Scholarly Publishing” from Committee on Publication Ethics (COPE), the Directory of Open Access Journals (DOAJ), the Open Access Scholarly Publishers Association (OASPA), and the World Association of Medical Editors (WAME) (https://doaj.org/bestpractice) if otherwise not described below.

- RESEARCH AND PUBLICATION ETHICS

- COPYRIGHTS, OPEN ACCESS, AND CLINICAL DATA SHARING POLICY

- SUBMISSION AND PEER REVIEW PROCESSES

- MANUSCRIPT PREPARATION

- MANUSCRIPT ACCEPTED FOR PUBLICATION

- ARTICLE PROCESSING CHARGES

- FEEDBACK AFTER PUBLICATION

- CONTACT INFORMATION

RESEARCH AND PUBLICATION ETHICS

For the policies on the research and publication ethics not stated in this instruction, “Good Publication Practice Guidelines for Medical Journals (http://kamje.or.kr)” or “COPE Core Practices (https://publicationethics.org/core-practices)” can be applied.

1. Authorship

It is important to understand that authorship credit should be based on (1) substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Every author should meet all of these four conditions for every submitted manuscript to CEO.

After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. Copyright assignment must also be completed by every author.

Correction of authorship: CEO does not correct authorship after publication unless a mistake has been made by the editorial staff. Authorship may be changed before publication but after submission when an authorship correction is requested by all of the authors involved with the manuscript.

2. Originality, plagiarism, and duplicate publication

Submitted manuscripts must not have been previously published in any context, or be under consideration for publication elsewhere. No part of the accepted manuscript should be duplicated in any other scientific journal without the express written permission of the Editorial Board. This restriction does not apply to abstracts or press reports published in connection with scientific meetings.

Submitted manuscripts are screened for possible plagiarism or duplicate publication by the use of Similarity Check upon arrival. If plagiarism or duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutions will be informed of this situation. There will also be penalties that will be assessed and applied for the authors if this incident occurs.

A letter of permission is required for any and all material that has been published previously. It is the responsibility of the author to request permission from the publisher for any material that is being reproduced or considered for reproduction by CEO. This requirement applies to text, figures, and tables.

……

更多详情:

https://www.e-ceo.org/authors/authors.php


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭